(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.45%.
Century Therapeutics's earnings in 2026 is -$107,779,000.On average, 8 Wall Street analysts forecast IPSC's earnings for 2026 to be -$85,542,286, with the lowest IPSC earnings forecast at -$97,211,242, and the highest IPSC earnings forecast at -$70,067,843. On average, 8 Wall Street analysts forecast IPSC's earnings for 2027 to be -$82,782,857, with the lowest IPSC earnings forecast at -$98,978,719, and the highest IPSC earnings forecast at -$53,024,314.
In 2028, IPSC is forecast to generate -$95,660,191 in earnings, with the lowest earnings forecast at -$132,560,785 and the highest earnings forecast at -$68,174,118.